Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 305-309 , April 2006

In vitro evaluation of nicotinic acetylcholine receptors with 2-[18F]F-A85380 in Parkinson's disease

  • Jörn Schmaljohann

      Affiliations

    • Department of Neurology, University of Bonn, Germany
    • Department of Nuclear Medicine, University of Bonn, Germany
    • Corresponding Author InformationCorresponding author. Department of Nuclear Medicine, University of Bonn, 53105 Bonn, Germany. Tel.: +49 228 2879859; fax: +49 228 2879096.
    • ,
  • Daniela Gündisch

      Affiliations

    • Department of Pharmaceutical Chemistry, University of Bonn, Germany
    • ,
  • Martina Minnerop

      Affiliations

    • Department of Neurology, University of Bonn, Germany
    • ,
  • Jan Bucerius

      Affiliations

    • Department of Nuclear Medicine, University of Bonn, Germany
    • ,
  • Alexius Joe

      Affiliations

    • Department of Nuclear Medicine, University of Bonn, Germany
    • ,
  • Michael Reinhardt

      Affiliations

    • Department of Nuclear Medicine, University of Bonn, Germany
    • ,
  • Stefan Guhlke

      Affiliations

    • Department of Nuclear Medicine, University of Bonn, Germany
    • ,
  • Hans-Jürgen Biersack

      Affiliations

    • Department of Nuclear Medicine, University of Bonn, Germany
    • ,
  • Ullrich Wüllner

      Affiliations

    • Department of Neurology, University of Bonn, Germany

Received 26 September 2005 ,Revised 5 December 2005 ,Accepted 6 December 2005.

References 

  1. Whitehouse PJ, Martino AM, Antuono PG, Lowenstein PR, Coyle JT, Price DL, et al. Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res. 1986;371:146–151
  2. Martin-Ruiz CM, Piggott M, Gotti C, Lindstrom J, Mendelow AD, Siddique MS, et al. Alpha and beta nicotinic acetylcholine receptors subunits and synaptophysin in putamen from Parkinson's disease. Neuropharmacology. 2000;39:2830–2839
  3. Pimlott SL, Piggott M, Owens J, Greally E, Court JA, Jaros E, et al. Nicotinic acetylcholine receptor distribution in Alzheimer's disease, dementia with Lewy bodies, Parkinson's disease, and vascular dementia: in vitro binding study using 5-[125I]-A-85380. Neuropsychopharmacology. 2004;29:108–116
  4. Court JA, Piggott MA, Lloyd S, Cookson N, Ballard CG, McKeith IG, et al. Nicotine binding in human striatum: elevation in schizophrenia and reductions in dementia with Lewy bodies, Parkinson's disease and Alzheimer's disease and in relation to neuroleptic medication. Neuroscience. 2000;98:79–87
  5. Quik M, Bordia T, Forno L, McIntosh JM. Loss of a-conotoxin MII- and A85380-sensitive nicotinic receptors in Parkinson's disease striatum. J Neurochem. 2004;88:668–679
  6. Halldin C, Någren K, Swahn CG, Långström B, Nyback H. (S)- and (R)-[11C]nicotine and the metabolite (R/S)-[11C]cotinine. Preparation, metabolites studies and in vivo distribution in human brain using PET. Nucl Med Biol. 1992;19:871–880
  7. Nybäck H, Halldin C, Ahlin A, Curvall M, Eriksson L. PET studies of the uptake of (S)- and (R)-[11C]nicotine in the human brain: difficulties in visualizing specific receptor binding in vivo. Psychopharmacology. 1994;115:31–36
  8. Horti AG, Ravert HT, London ED, Dannals RF. Synthesis of a radiotracer for studying nicotinic acetylcholine receptors: (±)-exo-2-(2-[18F]fluoro-5-pyridyl)-7-azabicyclo[2.2.1]heptane. Journal of Labelled Compounds and Radiopharmaceuticals. 1996;38:355–365
  9. Koren AO, Horti AG, Mukhin AG, Gündisch D, Kimes AS, Dannals RF, et al. 2-, 5-, and 6-Halo-3-(2(S)-azetidinylmethoxy)pyridines: synthesis, affinity for nicotinic acetylcholine receptors, and molecular modeling. J Med Chem. 1998;41:3690–3698
  10. Mukhin AG, Gündisch D, Horti AG, Koren AO, Tamagnan G, Kimes AS, et al. 5-Iodo-A-85380, an a4b2 subtype-selective ligand for nicotinic acetylcholine receptors. Mol Pharmacol. 2000;57:642–649
  11. Kimes AS, Horti AG, London ED, Chefer SI, Contoreggi C, Ernst M, et al. 2-[18F]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans. FASEB J. 2003;17:1331–1343
  12. Bottlaender M, Valette H, Roumenov D, Dolle F, Coulon C, Ottaviani M, et al. Biodistribution and radiation dosimetry of 18F-fluoro-A-85380 in healthy volunteers. J Nucl Med. 2003;44:596–601
  13. Schmaljohann J, Gündisch D, Minnerop M, Jessen F, Schütz C, Reinhardt M, et al. PET imaging of nicotinic acetylcholine α4β2 receptors in Alzheimer's and Parkinson's disease with 2-18F-A-85380. In: Vogt-Brodmann-Symposium, Jülich. 2004;(unpublished observation)
  14. Schmaljohann J, Minnerop M, Karwath P, Gündisch D, Falkai P, Guhlke S, et al. Imaging of central nAChReceptors with 2-[18F]F-A85380: optimized synthesis and in vitro evaluation in Alzheimer's disease. Appl Radiat Isot. 2004;61:1235–1240
  15. Wüllner U, Young AB, Penney JB, Beal MF. 3-Nitropropionic acid toxicity in the striatum. J Neurochem. 1994;63:1772–1781
  16. Paxinos G, Watson C. The rat brain in stereotaxic coordinates. San Diego: Academic Press; 1998;
  17. de Groote C, Wüllner U, Löschmann PA, Luiten PG, Klockgether T. Functional characterization and expression of thalamic GABA(B) receptors in a rodent model of Parkinson's disease. Neuropharmacology. 1999;38:1683–1689
  18. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197–211
  19. Perry DC, Kellar KJ. [3H]epibatidine labels nicotinic receptors in rat brain: an autoradiographic study. J Pharmacol Exp Ther. 1995;275:1030–1034
  20. Lukas RJ, Changeux JP, Le Novere N, Albuquerque EX, Balfour DJ, Berg DK, et al. International Union of Pharmacology. XX. Current Status of the Nomenclature for Nicotinic Acetylcholine Receptors and their Subunits. Pharmacol Rev. 1999;51:397–401
  21. Holladay MW, Dart MJ, Lynch JK. Neuronal nicotinic acetylcholine receptors as targets for drug discovery. J Med Chem. 1997;40:4169–4194
  22. Quik M, Sum JD, Whiteaker P, McCallum SE, Marks MJ, Musachio JL, et al. Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice. Mol Pharmacol. 2003;63:1169–1179
  23. Kulak JM, Muschio JL, McIntosh JM, Quik M. Declines in different 2* nicotinic receptor populations in monkey striatum after nigrostriatal damage. J Pharmacol Exp Ther. 2002;303:633–639
  24. Kulak JM, Sum J, Musachio JL, McIntosh JM, Quick M. 5-Iodo-A-85380 binds to α-conotoxin MII-sensitive nicotinic acetylcholine receptors (nAChRs) as well as α4β2* subtypes. J Neurochem. 2002;81:403–406
  25. Breit S, Reimold M, Reischl G, Klockgether T, Wüllner U, [11C]d-threo-methylphenidate PET in patients with Parkinson's disease and essential tremor. J Neural Transm. 2005 Jun 15; [Electronic publication ahead of print].

PII: S0969-8051(05)00299-4

doi: 10.1016/j.nucmedbio.2005.12.012

Nuclear Medicine and Biology
Volume 33, Issue 3 , Pages 305-309 , April 2006

Article Tools

* Image Usage & Resolution